Aytu BioPharma Q1 revenue beats estimates on higher EXXUA sales

By Reuters News


Overview

  • U.S. CNS drugmaker's fiscal Q1 revenue rose 6.9%, beating analyst expectations

  • Adjusted EBITDA loss for fiscal Q1 narrowed, beating analyst estimates

  • Company to be acquired by Rosemont Pharmaceuticals for $2.70 per share in cash


Outlook

  • Company did not provide specific guidance for future quarters or the full year in its press release


Result Drivers

  • EXXUA GROWTH - Co said Q1 revenue growth was driven by higher EXXUA sales and a 33% sequential increase in prescriptions

  • ADHD PORTFOLIO DECLINE - Co attributed lower ADHD portfolio revenue to reduced promotional emphasis and generic competition

  • PEDIATRIC PORTFOLIO IMPROVEMENT - Co said pediatric portfolio revenue increased due to improved payer mix and lower returns


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 Revenue

Beat

$14.84 mln

$13.27 mln (3 Analysts)

Q1 Net Loss

$3.88 mln

Q1 Adjusted EBITDA

Beat

-$2.60 mln

-$2.93 mln (3 Analysts)

Q1 Gross Profit

$9.44 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Aytu Biopharma Inc is $7.00, about 293.3% above its November 13 closing price of $1.78


Reuters Recommended Reads

  • Nov 16 - ALX Oncology Q3 net loss per share narrows

  • Nov 16 - Prelude Therapeutics Q3 net loss narrows as expenses fall

  • Nov 16 - Invivyd Q3 revenue rises on PEMGARDA demand, loss per share less than expected


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.